{"id":672,"date":"2015-11-05T18:37:06","date_gmt":"2015-11-05T18:37:06","guid":{"rendered":"http:\/\/blogs.cuit.columbia.edu\/ghrcca\/?p=672"},"modified":"2015-11-05T18:40:14","modified_gmt":"2015-11-05T18:40:14","slug":"social-intervention-group-receives-4-8-million-nih-grant-to-take-next-steps-in-fight-against-hiv-in-kazakhstan","status":"publish","type":"post","link":"https:\/\/blogs.cuit.columbia.edu\/ghrcca\/ru\/2015\/11\/05\/social-intervention-group-receives-4-8-million-nih-grant-to-take-next-steps-in-fight-against-hiv-in-kazakhstan\/","title":{"rendered":"Social Intervention Group Receives $4.8 million NIH Grant to Take Next Steps in Fight against HIV in Kazakhstan"},"content":{"rendered":"

The study will focus on 1) integrating HIV care with harm reduction treatments and 2) testing real-world effectiveness.<\/strong> \u00a0As HIV incidence in many countries has fallen over the past decade, it has continued to increase in Russia, Eastern Europe, and Central Asia, fueled mainly by injection drug use. The Social Intervention Group (SIG) of the Columbia School of Social Work has been actively engaged for more than ten years in the fight against this rapidly expanding epidemic in the Central Asian Republic of Kazakhstan, securing more than $9 million in funding to support a series of projects assisting researchers on the ground with testing evidence-based treatment methods. And now, with the help of a $4.8 million grant from the National Institute of Drug Abuse (NIDA) division of the National Institutes of Health (NIH), the SIG research team, led by Willma and Albert Musher Professor Nabila El-Bassel<\/a>, will be taking two important next steps. The first will be to integrate evidence-based HIV testing, treatment and care programs into harm reduction programs<\/a> across Kazakhstan.<\/p>\n

Currently, the majority of Kazakhstanis who inject drugs are more likely to seek out a harm reduction program, where a health care worker provides the drug user with clean syringes and needles, than to seek treatment for HIV. Only 28 percent of the estimated 123,574 people who inject drugs were tested for HIV in 2012, the last year for which statistics are available. Of those who turned out to be HIV-positive, fewer than 10 percent are currently engaged in HIV care and only 7 percent receive Antiretroviral Therapy.<\/p>\n

This study aims to close the critical gaps in HIV care for people who inject drugs by implementing evidence-based intervention strategies that widen access to HIV testing and counseling and by improving the linkage to HIV care in 24 harm reduction programs across Kazakhstan. The second step will be to examine the effectiveness of implementing evidence-based HIV testing and treatment programs as part of harm-reduction programs.<\/p>\n

The study ultimately aims to answer important questions for future wide-scale implementation, such as: Are these intervention strategies cost effective? Are there structural or organizational factors that get in the way? Can the model be scaled up for use in settings across Central Asia? \u201cScaling up integrated, cost-effective HIV services is urgently needed,\u201d said Professor El-Bassel. \u201cOur study uses a state-of-the art implementation research design and will have important public health implications for improving HIV service delivery in injection-driven epidemic countries, especially in Central Asia.\u201d<\/p>\n

The study will be led by Dr. Nabila El-Bassel and Dr. Louisa Gilbert<\/a> along with a team of co-Investigators that include:<\/p>\n